Cardiovascular safety trials of incretin-based drugs: What do they mean? - Wikidata - awgldk - TriplyDB

Cardiovascular safety trials of incretin-based drugs: What do they mean?

Cardiovascular safety trials of incretin-based drugs: What do they mean?

http://www.wikidata.org/entity/Q39406260

about

Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).

P2860

Q39164190-CC9AF73C-5BE0-4DCE-B00F-9F8E2A4F9F39 Q41540160-1A5E100C-B8B0-4ACF-97B8-06DC21B7067D

P2860

Cardiovascular safety trials of incretin-based drugs: What do they mean?

http://www.wikidata.org/entity/Q39406260

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@en

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@nl

type

label

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@en

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@nl

prefLabel

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@en

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@nl

P1433

Q39406260-8FCE60F0-49E0-481A-A654-99C3615EFCD3

P1476

Q39406260-A76F3DDC-F4D2-4B08-A2DD-95F862C3ECE0

P2093

Q39406260-E73C2F3E-4AC4-48EA-94E6-F4B99C0C3A2D

P2860

Q39406260-0C0393C5-C29E-448B-A709-C3AD348322A9

Q39406260-73BFC831-ACEF-4404-B9C7-88D79FDAEC96

Q39406260-7FA1A2DF-F2D8-431B-AE5A-242236835D3D

Q39406260-893A30AD-EDB3-4256-BD50-C0E4E4D3D552

Q39406260-898FAF47-022E-49D3-B874-74A9E1B929C6

Q39406260-9817A869-4D5A-4EA0-8D3C-3DB078CAFEE4

Q39406260-B2C05A10-A454-4B49-BD87-689E1848F826

Q39406260-D8CC8913-46BC-4DE3-94D1-56B435CCE943

Q39406260-DBCB94FC-B1C8-4F9C-8E00-A073DBC98E1D

P304

Q39406260-0C2A42FB-CFA8-486D-8F64-9C5B2304CE34

P31

Q39406260-D298FAFC-61DF-4AB5-BDF3-DE60D2B23701

P356

Q39406260-03065B36-4335-4F8D-B8B5-85229E77DE8B

P433

Q39406260-24739100-D218-464E-A2ED-D7053C62FDD5

P478

Q39406260-9A991397-864D-43BD-9208-12D73E3CF286

P50

Q39406260-2384E4C1-55F3-4298-9A1F-B42F4ACBC2D5

P577

Q39406260-A27A041D-FAD5-4EFB-A158-19413EACBE6E

P698

Q39406260-C44989C4-498B-4BDB-9ECD-31945BEE05DC

P932

Q39406260-23854BA6-3129-4635-922A-8FE3FAC8FF8F

P356

P1433

Journal of Diabetes Investigation

P1476

Cardiovascular safety trials of incretin-based drugs: What do they mean?

@en

P2093

Yutaka Seino

http://www.w3.org/2001/XMLSchema#string

P2860

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

P304

272-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDI.12576

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27612317

http://www.w3.org/2001/XMLSchema#string

P932

5415478

http://www.w3.org/2001/XMLSchema#string